The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of CPX-351 (cytarabine:daunorubicin) liposome injection in patients with acute myeloid leukemia >60 years of age who have not been treated with intensive chemotherapy.
 
Ellen K. Ritchie
Consulting or Advisory Role - Celgene; Incyte; Novartis; Pfizer
Speakers' Bureau - ARIAD; Celgene; Incyte; Novartis; Pfizer
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Jazz Pharmaceuticals; Novartis (Inst); NS Pharma (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Sangmin Lee
Consulting or Advisory Role - Stemline Therapeutics
 
Pinkal M. Desai
No Relationships to Disclose
 
Jeff Ball
No Relationships to Disclose
 
Michael S. Samuel
No Relationships to Disclose
 
Tania Curcio
No Relationships to Disclose
 
Sumaiya Miah
No Relationships to Disclose
 
Gail J. Roboz
Consulting or Advisory Role - Abbvie; Actinium Pharmaceuticals; Amgen; Amphivena; argenx; Array BioPharma; Astellas Pharma; Astex Pharmaceuticals; Bayer; Bayer; Celgene; Celltrion; Daiichi Sankyo; Eisai; Genentech/Roche; Genoptix; Janssen; Jazz Pharmaceuticals; MedImmune; MEI Pharma; Novartis; Orsenix; Otsuka; Pfizer; Roche; Sandoz; Takeda
Research Funding - Abbvie (Inst); Agios (Inst); amphivena (Inst); Astex Pharmaceuticals (Inst); Celgene (Inst); Cellectis (Inst); Cellectis (Inst); CTI (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); MEI Pharma (Inst); Moffitt (Inst); Novartis (Inst); Onconova Therapeutics (Inst); Pfizer (Inst); Sunesis Pharmaceuticals (Inst); Tensha Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; Amgen; Amphivena; Array BioPharma; Astex Pharmaceuticals; Bayer; Celgene; Celltrion; Clovis Oncology; Eisai; Janssen; Jazz Pharmaceuticals; Novartis; Pfizer; Roche/Genentech; Sandoz; Sunesis Pharmaceuticals